Search results
Results from the WOW.Com Content Network
Bristol Myers Squibb and Karuna announced their merger agreement on Friday. The transaction, which amounts to $330 per share in cash, offers a premium of 53% over Karuna's stock on Thursday.
By Michael Erman and Manas Mishra (Reuters) -Bristol Myers Squibb on Friday agreed to buy Karuna Therapeutics for $14 billion, gaining a promising new type of antipsychotic medicine to help power ...
Bristol Myers obtained drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last year. ... In Other News. Entertainment. Entertainment. People.
Xanomeline was licensed to Karuna Therapeutics in 2012 and KarXT was subsequently created as a dual drug formulation by adding trospium. Trospium is a non-brain-penetrant and non-selective muscarinic receptor blocker that may ameliorate the peripheral side effects of xanomeline.
The drugmaker gained access to the treatment, called KarXT, through its $14 billion deal to buy Karuna Therapeutics last year. "Current antipsychotic treatments are associated with a number of ...
She is the founder and CEO [1] of Seaport Therapeutics, [2] co-founder of Karuna Therapeutics, [3] and Founding CEO of PureTech Health. [4] She sits on the board of BIO [5] and is a co-founder and host of Biotech Hangout. [6] She was named one of the most influential people in Biopharma in 2023. [7] MIT Technology Review TR35 top innovators .
[19] [20] As of 2020, he was on the board of directors or is a trustee of several organizations, including serving as chairman of the Board of the Foundation for the NIH (FNIH) [21] and as a Director of Alnylam Pharmaceuticals, [22] Sage Therapeutics, [23] Voyager Therapeutics [24] and Karuna Pharmaceuticals. [25]
The promising drug combination was discovered and tested by Karuna Therapeutics, ... CBS News. Man wanted for questioning in UnitedHealthcare CEO shooting, police say. News. ABC News.